RPL14P3

Across TCGA pan-cancer cohorts, RPL14P3 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated RPL14P3 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RPL14P3 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL14P3 expression acts as an unfavorable survival marker, although some lineages such as KIRC and SKCM show a favorable association.

LIHC, SARC, and KIRC are the cancer types where RPL14P3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.343	0.526	<.001	76	view →
SARC	OS	Tertile	All	0.582	0.850	<.001	25	view →
KIRC	DFS	Quartile	III,IV	0.679	0.318	.009	22	view →
SKCM	OS	Median	All	0.904	0.837	.005	18	view →
KICH	OS	Median	All	0.765	0.971	.011	13	view →
UVM	DFS	Median	All	0.713	0.406	.009	12	view →
THYM	OS	Tertile	All	1.000	0.925	.023	8	view →
COAD	OS	Quartile	All	0.949	0.835	.016	8	view →
CHOL	DFS	Median	All	0.233	0.719	.030	6	view →
ACC	OS	Median	III,IV	0.788	0.431	.032	6	view →
STAD	DFS	Quartile	All	0.345	0.561	.036	4	view →
READ	DFS	Tertile	III,IV	0.938	0.573	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

RPL14P3–LIHC (DFS)

Open the LIHC breakdown →